Hepatic mitochondrial function and brain tumours

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 10, Issue 4, 2007, Pages 475-479

  Pouliquen, Daniel L ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c INSTITUT DE BIOLOGIE   (France)

Author keywords

Cachexia; Gliomas; Immune defects; Liver; Mitochondria

Indexed keywords

CYTOKINE; EICOSAPENTANOIC ACID; GAMMA LINOLENIC ACID; ION; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VALERIC ACID DERIVATIVE; WATER;

ANOREXIA; BIOGENESIS; BIOLOGICAL MODEL; BRAIN TUMOR; CACHEXIA; CELL ACTIVITY; CELL PROTECTION; ENERGY CONSERVATION; ENERGY CONSUMPTION; FATIGUE; GLIOMA; HUMAN; IMMUNE SYSTEM; LIVER FUNCTION; LIVER METABOLISM; LIVER MITOCHONDRION; LIVER WEIGHT; NONHUMAN; PATIENT CARE; REVIEW; SLEEP DEPRIVATION; TUMOR CELL; TUMOR GROWTH; WASTING SYNDROME;

BRAIN NEOPLASMS; CACHEXIA; CHRONIC DISEASE; CYTOKINES; DISEASE PROGRESSION; GLIOMA; HUMANS; LIVER; MITOCHONDRIA, LIVER;

RATTUS;

EID: 34250651616     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328108f452     Document Type: Review

References (50)

1. Al-Waili NS, Butler GJ. A combination of radiotherapy, nitric oxide and a hyperoxygenation sensitizing protocol for brain malignant tumor treatment. Med Hypotheses 2007; 68:528-537.
2. Deorah S, Lynch CF, Sibenaller ZA, et al. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End results Program, 1973 to 2001. Neurosurg Focus 2006; 20:E1. This is an interesting recent study on epidemiology of brain tumours and survival rates of patients in the USA.
3. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999; 26:348-357.
4. Kaneko S, Nomura K, Yoshimura T, et al. Trend of brain tumor incidence by histological subtypes in Japan: estimation from the Brain Tumor Registry of Japan, 1973-1993. J Neurooncol 2002; 60:61-69.
5. Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006; 98:1528-1537.
6. Brandes AA, Compostela A, Blatt V, Tosoni A. Glioblastoma in the elderly: Current and future trends. Crit Rev Oncol Hematol 2006; 60:256-266. This interesting paper reports on prognostic factors and care of elderly patients with glioblastoma.
7. Stupp R, Van Den Bent MJ, Weller M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005; 352:987-996.
8. Sausville EA, Burger AM. Contributions of humantumor xenografts to anticancer drug development. Cancer Res 2006; 66:3351-3354.
9. Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 2006; 66:3355-3358.
10. Aldape K, Colman H, James CD. Models of malignant glioma. Cancer 2006; 3:191-196. This outstanding study shows the limits of in-vitro models of glioma.
11. Landriscina M, Remiddi F, Ria F, et al. The level of MnSOD is directly correlated with grade of brain tumors of neuroepithelial origin. Br J Cancer 1996; 74:1877-1885.
12. Yoshii Y, Saito A, Zhao DW, et al. Copper/zinc superoxide dismutase, nuclear DNA content, and progression in human gliomas. J Neurooncol 1999; 42:103-108.
13. Kinnula VL, Crapo JD. Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med 2004; 36:718-744.
14. Kennedy PG, Watkins BA, Thomas DG, et al. Antigenic expression by cells derived from human gliomas does not correlate with morphological classification. Neuropathol Appl Neurobiol 1987; 13:327-347.
15. Anderson RC, Elder JB, Brown MD, et al. Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro. Clin Immunol 2002; 102:84-95.
16. Sandberg R, Ernberg I. The molecular portrait of in vitro growth by metaanalysis of gene-expression profiles. Genome Biol 2005; 6:R65.
17. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999; 100: 216-232.
18. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66:3294-3302. The authors report outstanding work on deficiencies in T cell function induced by malignant gliomas.
19. Roussel E, Gingras MC, Grimm EA, et al. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 1996; 105:344-352.
20. Argiles JM, Busquets S, Lopez-Soriano FJ. The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol 2005; 37:2036-2046.
21. Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in malignant glioma: a target for antitumor therapy? Crit Rev Oncol Hematol 2006; 59:181-193.
22. De Palma M, Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 2006; 1766:159-166. An interesting review of recent findings on tumor angiogenesis is presented.
23. Slettenaar VIF, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug deliv Rev 2006; 58:962-974.
24. Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72:1605-1621. This is a complete descriptive review of the critical link between inflammation and cancer, including gliomas.
25. Nabors LB, Suswam E, Huang Y, et al. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res 2003; 63:4181-4187.
26. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-776.
27. Pouliquen D, Olivier C, Debien E, et al. Changes in liver mitochondrial plasticity induced by brain tumor. BMC Cancer 2006; 6:234.
28. Saini A, Nasser A-S, Stewart CEH. Waste management-cytokines, growth factors and cachexia. Cytokine Growth Fact Rev 2006; 17:475-486. This paper is an important contribution to our understanding of the role of TNF-α in the cachectic state in cancer.
29. Snodgrass-Belt P, Gilbert JL, Davis FC. Central administration of transforming growth factor-alpha and neuregulin-1 suppress active behaviors and cause weight loss in hamsters. Brain Res 2005; 1038:171-182.
30. Hadden JW. Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol 2003; 3:1061-1071.
31. Bongaerts GPA, van Halteren HK, Verhagen CAM, et al. Cancer cachexia demonstrates the energetic impact of gluconeogenesis in human metabolism. Med Hypotheses 2006; 67:1213-1222. This outstanding review presents an hypothesis regarding the energetic consequences of the growing tumour and of metabolic adaptation in the liver.
32. Roh MS, Ekman L, Jeevanandam M, Brennan MF. Gluconeogenesis in tumorinfluenced hepatocytes. Surgery 1984; 96:427-434.
33. Blumberg D, Burt ME, Kher U, Brennan MF. Tolbutamide inhibits gluconeogenesis in the tumor-influenced hepatocyte. J Surg Res 1993; 55:565-569.
34. Fischer CP, Bode BP, Hurley BP, Souba WW. Alterations in oxidative metabolism and glutamine transport support glucose production in the tumor-influenced hepatocyte. J Surg Res 1997; 69:379-384.
35. Mehta R, Templeton DM, O'Brien PJ. Mitochondrial involvement in genetically determined transition metal toxicity. II. Copper toxicity. Chem Biol Interact 2006; 163:77-85.
36. Wrona D. Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune systems. J Neuroimmunol 2006; 172:38-58.
37. Guijarro A, Laviano A, Meguid MM. Chapter 22: Hypothalamic integration of immune function and metabolism. Prog Brain Res 2006; 153:367-405. This is a well documented review on the relationships between immune cellderived cytokines, their peripheral action, and regulation of metabolism.
38. VanItallie TB. Sleep and energy balance: interactive homeostatic systems. Metabolism 2006; 55:S30-S35.
39. Jatoi A. Fish oil, lean tissue, and cancer: is there a role for eicosapentaenoic acid in treating the cancer anorexia/weight loss syndrome? Crit Rev Oncol Hematol 2005; 55:37-43.
40. Smith HJ, Greenberg NA, Tisdale MJ. Effect of eicosapentaenoic acid, protein and aminoacids on protein synthesis and degradation in skeletal muscle of cachectic mice. Br J Cancer 2004; 91:408-412.
41. Higushi Y. Polyunsaturated fatty acids promote 8-hydroxy-2deoxyguanosine formation through lipid peroxidation under the glutamate-induced depletion in rat glioma cells. Arch Biochem Biophys 2001; 392:65-70.
42. Das UN. From bench to the clinic: γ-linolenic acid therapy of human gliomas. Prostaglandins Leukot Essent Fatty acids 2004; 70:539-552.
43. Maret W, Sandstead HH. Zinc requirements and the risks and benefits of zinc supplementation. J Trace Elem Med Biol 2006; 20:3-18.
44. Maret W. Cellular zinc and redox states converge in the metallothionein/ thionein pair. J Nutr 2003; 133:1460S-1462S.
45. Loo G. Redox-sensitive mechanisms of phytochemical-mediated inhibition of cancer cell proliferation. J Nutr Biochem 2003; 14:64-73.
46. Issa AY, Volate SR, Wargovich MJ. The role of phytochemicals in inhibition of cancer and inflammation: new directions and perspectives. J Food Comp Anal 2006; 19:405-419. This critical review summarizes some of the molecular mechanisms through which several phytochemicals may inhibit cancer and inflammation.
47. Wei Q-Y, Chen W-F, Zhou B, et al. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta 2006; 1760:70-77.
48. Belkaid A, Copland IB, Massillon D, Annabi B. Silencing of the human microsomal glucose-6-phosphate translocase induces glioma cell death: potential new anticancer target for curcumin. FEBS Lett 2006; 580:3746-3752.
49. Nebeling LC, Miraldi F, Shurin SB, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 1995; 14:202-208.
50. Seyfried TN, Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab (Lond) 2005; 2:30.